1372540-24-3

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-methyl-1-[2-methyl-3-(trifluoromethyl)phenyl]methyl-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylate is used as a potential pharmaceutical compound for its unique structural features, which may offer novel therapeutic applications. Its specific chemical composition could allow it to interact with biological targets in ways that are not yet fully understood, necessitating further research to explore its medicinal potential.
Used in Research Applications:
In the field of scientific research, methyl 2-methyl-1-[2-methyl-3-(trifluoromethyl)phenyl]methyl-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylate serves as a valuable chemical entity for studying the effects of its structural components on various biological systems. Its potential as a ligand makes it a candidate for investigations into receptor binding, enzyme inhibition, or other interactions that could reveal new insights into its functionality and possible applications.

Upstream product

• 261952-16-3 1-(bromomethyl)-2-methyl-3-(trifluoromethyl)benzene 
• 1372540-21-0 methyl 2-methyl-5-(4-morpholinyl)-1H-benzimidazole-7-carboxylate 
• 1203486-58-1 methyl 3-amino-5-(4-morpholinyl)-2-nitrobenzoate 
• 874301-23-2 3-amino-5-chloro-2-nitrobenzoic acid methyl ester 
• 2516-95-2 5-chloro-2-nitrobenzoic acid 

Downstream Products

• 1372540-91-4 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid 2-amino-2-(hydroxymethyl)-1,3-propanediol salt 
• 1372540-34-5 C₂₂H₂₁ClF₃N₃O₂ 
• 1372540-32-3 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzimidazole 
• 1372540-33-4 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxamide 
• 1372540-84-5 2-methyl-4-[(methyloxy)methyl]-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole 
• 1372540-93-6 ethyl 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylate 
• 1372540-40-3 [2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazol-4-yl]methanol 
• 1372540-25-4 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(morpholin-4-yl)-1H-1,3-benzodiazole-4-carboxylic acid 

Relevant academic research and scientific papers

Combination Drug Therapy

A novel combination comprising the 17 α-hydroxylase/C17,20 lyase inhibitor, (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol or a pharmaceutically acceptable salt or solvate thereof, with a PI3Kβ inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 α-hydroxylase/C17,20 lyase and/or PI3Kβ is beneficial, e.g., cancer.

COMBINATION DRUG THERAPY

A novel combination comprising the androgen receptor inhibitor, 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide or a pharmaceutically acceptable salt or solvate thereof, with a PI3K? inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of androgen receptor and/or PI3K? is beneficial, e.g., cancer.

BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kβ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazoles compounds for treating cancer.